Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase in Chronic Gouty Arthritis
NCT05312268Phase 4Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rasburicase in gouty arthritis (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Monosodium urate crystal volume change evaluated by dual energy CT at 24 weeks. Status: unknown.
02
Drugs
rasburicase
03
Conditions
gouty arthritis
Beyond the preview
Go deeper on NCT05312268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312268.